RVTY

REVVITY, INC.
2 filings tracked
healthcarebiotechnologyLARGE ($10B-200B)

Signal Magnitude Chart

BULLISH | 70% | 5/12/2026 | earnings beatBEARISH | 80% | 5/12/2026 | margin compressionBULLISH | 60% | 5/12/2026 | buybackBEARISH | 90% | 5/12/2026 | debt restructureBULLISH | 50% | 5/12/2026 | acquisitionBULLISH | 70% | 5/12/2026 | earnings beatBEARISH | 80% | 5/12/2026 | margin compressionBULLISH | 60% | 5/12/2026 | buybackBEARISH | 90% | 5/12/2026 | debt restructureBULLISH | 50% | 5/12/2026 | acquisitionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 12

Total revenue increased 7% to $711.1 million, driven by growth in both reportable segments.

earnings beat
70%
bearishMay 12

Gross margins fell 200 basis points to 54.5% due to tariffs and product mix shifts.

margin compression
80%
bullishMay 12

Active share repurchase program with $800.5 million remaining available.

buyback
60%
bearishMay 12

Significant debt maturity of $575.8 million due in July 2026.

debt restructure
90%
bullishMay 12

Acquisition of ACD/Labs to expand software and informatics capabilities.

acquisition
50%
bullishMay 12

Total revenue increased 7% to $711.1 million, driven by growth in both reportable segments.

earnings beat
70%
bearishMay 12

Gross margins fell 200 basis points to 54.5% due to tariffs and product mix shifts.

margin compression
80%
bullishMay 12

Active share repurchase program with $800.5 million remaining available.

buyback
60%
bearishMay 12

Significant debt maturity of $575.8 million due in July 2026.

debt restructure
90%
bullishMay 12

Acquisition of ACD/Labs to expand software and informatics capabilities.

acquisition
50%